Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy.
The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy. Rheumatology (Oxford). 2018 07 01; 57(suppl_5):v2-v8.
View in:
PubMed
subject areas
Antirheumatic Agents
Antirheumatic Agents
Drug Labeling
Drug Labeling
Female
Female
Humans
Humans
Maternal Exposure
Maternal Exposure
Pregnancy
Pregnancy
Pregnancy Complications
Pregnancy Complications
Rheumatic Diseases
Rheumatic Diseases
Risk Assessment
Risk Assessment
United States
United States
United States Food and Drug Administration
United States Food and Drug Administration
authors with profiles
Eliza Chakravarty